Equities

Notable Labs Ltd

NTBL:NAQ

Notable Labs Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.81
  • Today's Change-0.150 / -15.63%
  • Shares traded6.65k
  • 1 Year change+276.74%
  • Beta0.9719
Data delayed at least 15 minutes, as of May 23 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Notable Labs Ltd, formerly Vascular Biogenics Ltd, is an Israel-based clinical-stage biopharmaceutical company committed to developing next-generation, targeted medicines for difficult-to-treat medical conditions. The Company has created a pipeline of therapeutics that address cancer and immune-inflammatory diseases with the goal of significantly improving patient outcomes and overcoming the limitations of approved treatments. The Company's product candidates are built off of two platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications.

  • Revenue in USD (TTM)311.00k
  • Net income in USD-12.39m
  • Incorporated2000
  • Employees16.00
  • Location
    Notable Labs Ltd320 Hatch DriveFOSTER CITY 94404United StatesUSA
  • Phone+1 (415) 851-2410
  • Fax+972 8993-5001
  • Websitehttps://notablelabs.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
NLS Pharmaceutics AG0.00-12.17m6.86m3.00---------0.3188-0.31880.00-0.27240.00----0.00-218.86-272.62---------------81.34--------26.21------
Scorpius Holdings Inc2.23m-46.05m6.86m77.00--0.0749--3.08-1.78-2.000.08591.390.0234--0.676228,918.57-50.05-38.42-61.25-42.0629.10---2,136.28-703.02----0.2305--202.1233.24-23.85--218.50--
Cell MedX Corp70.00-96.91k6.90m0.00------98,512.63-0.0029-0.00290.00-0.00240.0015-------202.28-792.55-----685.71---138,442.90-3,681.84---3.17-----54.53--29.01------
Tenax Therapeutics Inc0.00-10.10m6.97m5.00--0.5609-----24.52-24.520.006.350.00----0.00-67.96-199.16-75.66-285.64-----------105.120.0322------30.21------
Longeveron Inc978.00k-21.62m7.11m23.00--0.9275--7.27-9.58-9.580.42971.210.0621--7.1442,521.74-132.19-63.15-184.16-75.6848.4733.70-2,129.24-441.02----0.00---41.98-19.78-17.92--26.80--
Kazia Therapeutics Ltd (ADR)14.90k-13.52m7.12m12.00--0.7734--477.59-0.82-0.820.00080.34910.0007--73.97---63.98-46.35-82.39-54.75-----90,714.45-497.17----0.1297--979.43-28.3118.19------
Pulmatrix Inc11.68m-8.85m7.16m22.00--0.3764--0.6127-2.42-2.423.205.210.3517--17.84531,090.90-26.63-46.91-30.21-58.12-----75.73-238.04----0.00--20.21116.6225.03--104.29--
Shuttle Pharmaceuticals Holdings Inc0.00-6.59m7.16m8.00--1.69-----0.441-0.4410.000.25240.00----0.00-90.28---104.75-------------49.560.1527-------112.71------
Intelligent Bio Solutions Inc2.83m-10.03m7.18m17.00--0.6033--2.54-64.14-64.144.603.820.20412.697.77166,299.40-72.67-80.65-107.67-224.8423.33---356.09-948.541.87--0.0451--187.51367.97-28.00------
Cannabis Bioscience Internatnl Hlgs Inc56.94m6.94m7.27m389.000.00130.00010.78770.12760.53280.53284.294.920.591762.811.45146,384.307.83--11.73--31.96--13.24--0.685650.750.0631--12.79--177.84------
Notable Labs Ltd311.00k-12.39m7.30m16.00--0.6327--23.49-2.31-2.310.06221.280.0142----19,437.50-56.70-52.02-74.10-62.0937.3060.19-3,984.24-3,636.93----0.0271---52.89-11.9365.13---50.69--
Protagenic Therapeutics Inc0.00-6.01m7.41m----3.47-----1.37-1.370.000.48080.00-------117.26-74.49-140.56-92.56-----------11.500.00-------40.64------
NuCana PLC (ADR)0.00-33.78m7.44m25.00---------301.88-301.880.00--0.00----0.00-72.34-41.01-125.17-48.07------------0.0324------13.71---21.70--
Trevena Inc3.14m-40.15m7.65m23.00------2.44-2.71-2.710.2107-0.79990.0904----136,478.30-115.65-55.93-148.14-66.3548.04---1,279.01-3,134.41---15.391.88--847.61-11.4324.93---24.67--
National Graphite Corp0.00-1.97m7.72m0.00---------0.0221-0.02210.00-0.01930.00-------11,014.44-212.13---6,295.18---------------------1,432.70------
Entero Therapeutics Inc0.00-6.44m7.76m15.00--0.3529-----51.90-51.900.0038.450.00----0.00-12.74-295.92-14.01-1,599.51-----------265.690.0802-------7.55------
Data as of May 23 2024. Currency figures normalised to Notable Labs Ltd's reporting currency: US Dollar USD

Institutional shareholders

1.56%Per cent of shares held by top holders
HolderShares% Held
Squarepoint OPS LLCas of 31 Mar 202463.70k0.71%
Mariner LLCas of 31 Mar 202422.00k0.24%
Morgan Stanley & Co. LLCas of 31 Mar 202419.30k0.21%
Two Sigma Securities LLCas of 31 Mar 202414.44k0.16%
XTX Markets LLCas of 31 Mar 202410.19k0.11%
Wells Fargo Clearing Services LLCas of 31 Mar 20245.00k0.06%
UBS Securities LLCas of 31 Mar 20243.93k0.04%
Group One Trading LPas of 31 Mar 20241.27k0.01%
Securities America Advisors, Inc.as of 31 Mar 2024630.000.01%
Harel Mutual Funds Ltd.as of 31 Mar 2024314.000.00%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.